EnBiotix, Inc., a rare disease company currently focused on chronic respiratory disorders, announced the closing of an $11M pre-merger, convertible note round of financing comprised of Vectura Group plc, the Cystic Fibrosis Foundation and Sanford Biosciences LLC.
December 29, 2021
· 5 min read
